Achieve Life Sciences (QUIT) Stock Price, News & Analysis

Company Overview

Achieve Life Sciences is a clinical-stage biopharmaceutical company focused on developing treatments for nicotine dependence. Its lead product candidate, cytisinicline, is being studied as a potential aid for people seeking to stop smoking or using other nicotine products.

Cytisinicline is a plant-derived compound that acts on nicotine receptors in the brain. The company is conducting clinical development with the goal of obtaining regulatory approval; the candidate is not an approved treatment.

Achieve’s work centers on developing cytisinicline for markets including the United States. The compound has a history of use for smoking cessation in some countries outside the United States, while Achieve is pursuing its own clinical and regulatory pathway.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: $709.72 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: N/A
• Industry: N/A
• Sub-Industry: N/A
• Current Symbol: NASDAQ:QUIT
• CIK: N/A
• Web: www.achievelifesciences.com
• Phone: (425) 686-1500
• Fax: N/A
• Employees: 28
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 110,034,457
• Free Float: N/A
• Market Cap: $709.72 million
• Optionable: N/A
• Beta: N/A